A study of SX-682 with proton radiation therapy for leptomeningeal disease
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new drug (SX-682) combined with proton radiation therapy for people whose cancer has spread to the fluid around the brain and spinal cord. The goal is to see if this combination can help control the disease better. You can join if you have melanoma or non-small cell lung cancer that has spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have melanoma or non-small cell lung cancer that has spread to the lining of the brain or spinal cord (called leptomeningeal disease).
- You should be able to take care of yourself (though you may need some help).
- Your organs (like blood cells, kidneys, and liver) must be working well enough.
- You must be able to swallow pills.
- It must be safe for you to have an MRI with contrast.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (loncastuximab tesirine and rituximab) given after focused radiation (SRS) for people with CNS lymphoma that has come back or not responded to treatment, or who cannot get standard high-dose methotrexate. The goal is to see if this approach is safe and effective.
This trial tests SX-682 plus pembrolizumab (an immunotherapy) to treat metastatic or recurrent non-small cell lung cancer (NSCLC). It aims to see how well the combination works and whether it can shrink or control the cancer in people whose tumors have enough PD-L1.
This trial tests proton radiation to treat cancer that has spread into the thin lining around the brain and/or spinal cord (leptomeningeal metastasis). It may help control disease in that area while aiming to better protect surrounding healthy tissue.
This trial tests a combination of proton radiation to the brain and spine plus chemotherapy given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the lining of the brain and has continued to grow despite taking a third-generation TKI medicine like osimertinib.
This trial tests a new drug combination (SX-682 plus atezolizumab) for people with advanced non-small cell lung cancer that has grown after standard treatments like immunotherapy and chemotherapy. It aims to see if the combination can help shrink or slow the cancer.
This trial compares a newer type of radiation (proton therapy) to standard radiation for people whose breast or lung cancer has spread to the lining of the brain and spinal cord. It aims to see if proton therapy can better control the disease while causing fewer side effects.
Hear when a new Leptomeningeal Disease (LMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.